Bayer says its drug candidate for chronic cough – eliapixant – has hit the mark in a phase 2b trial, putting it in hot pursuit of Merck & Co's gefapixant, which was filed for approval in March.

Merck filed for approval of gefapixant in March 2021 on the strength of a pair of phase 3 trials – COUGH-1 and COUGH-2 – which found that the drug reduced 24-hour cough frequency by 18% and 15 ...

Ten to 15 years ago, I had to constantly clear my throat and it was driving me and everybody around me nuts. You had written ...

An occasional cough helps clear irritants and secretions from your lungs and prevents infection. But if you develop a chronic cough that persists for weeks, you should find out if you have a medical ...

Ten to 15 years ago, I had to constantly clear my throat and it was driving me and everybody around me nuts. You had written ...

Ten to 15 years ago, I had to constantly clear my throat and it was driving me and everybody around me nuts. You had written a column about chronic throat-clearing. In the article, you talked about ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

Posting to TikTok for his 237,000 followers, Doctor Sooj said: ": "I have seen so many people with a chronic cough recently, ...

You can get in touch with Jesus by emailing [email protected] A nationwide class-action lawsuit settlement could bring payments to consumers who purchased Robitussin cough medicine products ...

In this article, we are going to take a look at where Merck & Co. Inc. (NYSE:MRK) stands against other high growth forever dividend stocks. Dividend stocks have trailed the broader market over the ...

Most people probably would not connect seasonal allergies with their hearts. Itchy, watery eyes and stuffy noses, sure — but ...